Patents by Inventor Pui Yee Ng

Pui Yee Ng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES
    Publication number: 20240317752
    Abstract: The present disclosure relates compounds of Formula (I?): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds, e.g., in the treatment of cancer.
    Type: Application
    Filed: February 18, 2022
    Publication date: September 26, 2024
    Applicant: Black Diamond Therapeutics, Inc.
    Inventors: Pui Yee NG, Ivan JEWETT, Matthew C. LUCAS, Fernando PADILLA, Istvan J. ENYEDY
  • Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
    Patent number: 11919839
    Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: March 5, 2024
    Assignee: VALO HEALTH, INC.
    Inventors: Kenneth W. Bair, Nicholas Barczak, Bingsong Han, David R. Lancia, Jr., Cuixian Liu, Matthew W. Martin, Pui Yee Ng, Aleksandra Rudnitskaya, Jennifer R. Thomason, Mary-Margaret Zablocki, Xiaozhang Zheng
  • 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
    Patent number: 11891365
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: February 6, 2024
    Assignee: VALO HEALTH, INC.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Heather Davis, Aleksandra Rudnitskaya, David R. Lancia, Jr., Kenneth W. Bair, David S. Millan, Matthew W. Martin
  • 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS
    Publication number: 20230414585
    Abstract: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
    Type: Application
    Filed: June 29, 2023
    Publication date: December 28, 2023
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Mary-Margaret Zablocki
  • [6,6] FUSED BICYCLIC HDAC8 INHIBITORS
    Publication number: 20230406830
    Abstract: The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2?, L, X, W, Y1, Y2, Y3, and Y4 are described herein.
    Type: Application
    Filed: January 13, 2023
    Publication date: December 21, 2023
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Jennifer R. Downing, Mary-Margaret Zablocki, Bingsong Han, Nicholas Barczak, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, JR., Kenneth W. Bair
  • BICYCLIC [4,6,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS
    Publication number: 20230357216
    Abstract: The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II: where R, L, X1, X2, X3, X4, X5, Y1, Y2, Y3, and Y4 are described herein.
    Type: Application
    Filed: May 12, 2023
    Publication date: November 9, 2023
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Aleksandra Rudnitskaya, David R. Lancia, JR.
  • 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
    Patent number: 11730721
    Abstract: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: August 22, 2023
    Assignee: Valo Health, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Mary-Margaret Zablocki
  • ISOINDOLINES AS HDAC INHIBITORS
    Publication number: 20230242512
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs), having the formula: wherein Z, X1, X2, Y1, Y2, Y3, L, Z, and R are described herein.
    Type: Application
    Filed: November 9, 2022
    Publication date: August 3, 2023
    Inventors: Xiaozhang Zheng, Matthew W. Martin, Pui Yee Ng, Jennifer R. Thomason, Bingsong Han, Aleksandra Rudnitskaya, David R. Lancia, JR.
  • Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
    Patent number: 11702412
    Abstract: The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II: where R, L, X1, X2, X3, X4, X5, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: July 18, 2023
    Assignee: Valo Health, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Aleksandra Rudnitskaya, David R. Lancia, Jr.
  • Isoindolines as HDAC inhibitors
    Patent number: 11535607
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs), having the formula: (I) wherein Z, X1, X2, Y1, Y2, Y3, L, Z, and R are described herein.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: December 27, 2022
    Assignee: Valo Health, Inc.
    Inventors: Xiaozhang Zheng, Matthew W. Martin, Pui Yee Ng, Jennifer R. Thomason, Bingsong Han, Aleksandra Rudnitskaya, David R. Lancia, Jr.
  • Carboxamides as ubiquitin-specific protease inhibitors
    Patent number: 11524966
    Abstract: The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: December 13, 2022
    Assignee: Valo Health, Inc.
    Inventors: David J. Guerin, Pui Yee Ng, Zhongguo Wang, Tatiana Shelekhin, Justin Caravella, Hongbin Li, Stephanos Ioannidis, Mary-Margaret Zablocki
  • 3-ALKYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS
    Publication number: 20220363651
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Application
    Filed: April 23, 2021
    Publication date: November 17, 2022
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Heather Davis, Aleksandra Rudnitskaya, David R. Lancia, JR., Kenneth W. Bair, David S. Millan, Matthew W. Martin
  • [6,6] fused bicyclic HDAC8 inhibitors
    Patent number: 11414392
    Abstract: The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2?, L, X, W, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: August 16, 2022
    Assignee: Valo Health, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Jennifer R. Thomason, Mary-Margaret Zablocki, Bingsong Han, Nicholas Barczak, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., Kenneth W. Bair
  • METHODS USING HDAC11 INHIBITORS
    Publication number: 20220235018
    Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.
    Type: Application
    Filed: April 1, 2022
    Publication date: July 28, 2022
    Inventors: Jennifer Lee, Nicholas Barczak, Jaime A. Escobedo, Chiara Conti, Bingsong Han, David R. Lancia, JR., Cuixian Liu, Matthew W. Martin, Pui Yee Ng, Aleksandra Rudnitskaya, Jennifer R. Thomason, Xiaozhang Zheng
  • 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS
    Publication number: 20220204461
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Application
    Filed: March 10, 2022
    Publication date: June 30, 2022
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, JR., David S. Millan, Matthew W. Martin
  • Methods using HDAC11 inhibitors
    Patent number: 11345672
    Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: May 31, 2022
    Assignee: Valo Health, Inc.
    Inventors: Jennifer Lee, Nicholas Barczak, Jaime A. Escobedo, Chiara Conti, Bingsong Han, David R. Lancia, Jr., Cuixian Liu, Matthew W. Martin, Pui Yee Ng, Aleksandra Rudnitskaya, Jennifer R. Thomason, Xiaozhang Zheng
  • Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors
    Patent number: 11325917
    Abstract: The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: (I), where R1, R2, R3, R4, R4?, R5, R6, X, and n are described herein.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: May 10, 2022
    Assignee: VALO HEALTH, INC.
    Inventors: David Joseph Guerin, Kenneth W. Bair, Justin A. Caravella, Stephanos Ioannidis, David R. Lancia, Jr., Hongbin Li, Steven Mischke, Pui Yee Ng, David Richard, Shawn E. R. Schiller, Tatiana Shelekhin, Zhongguo Wang
  • 3-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
    Patent number: 11279681
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: March 22, 2022
    Assignee: Valo Health, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., David S. Millan, Matthew W. Martin, Kenneth W. Bair
  • 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
    Patent number: 11274084
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: March 15, 2022
    Assignee: Valo Health, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., David S. Millan, Matthew W. Martin
  • 3-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
    Patent number: 11274085
    Abstract: The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: March 15, 2022
    Assignee: Valo Health, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., David S. Millan, Matthew W. Martin